Vivos Therapeutics (VVOS) EBT Margin (2020 - 2026)
Vivos Therapeutics (VVOS) reported EBT Margin of 150.77% for Q1 2026, down 2265.0% year-over-year from 6.96% in Q1 2025, and up 17.09% on a QoQ basis from 181.85% in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of EBT Margin data on file, last reported at 150.77% in Q1 2026.
- Quarterly EBT Margin fell 2265.0% year-over-year to 150.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 128.36% (down 5115.0% YoY) and the FY2025 annual result came in at 121.71%, down 4724.0% from the prior year.
- EBT Margin grew to 150.77% in Q1 2026 per VVOS's latest filing, from 181.85% in the prior quarter.
- Across five years, EBT Margin topped out at 288.39% in Q4 2023 and bottomed at 181.85% in Q4 2025.
- The 5-year median for EBT Margin is 127.98% (2022), against an average of 91.33%.
- The widest annual swing landed in 2023, when EBT Margin surged 44254 bps; it then slumped 36641 bps in 2024.
- Tracing VVOS's EBT Margin over 5 years: stood at 154.15% in 2022, then soared by 287 bps to 288.39% in 2023, then slumped by 127 bps to 78.02% in 2024, then sank by 133 bps to 181.85% in 2025, then rose by 17 bps to 150.77% in 2026.
- Per Business Quant, the three latest VVOS EBT Margin figures stand at 150.77% (Q1 2026), 181.85% (Q4 2025), and 79.61% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 15.57% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 27.84% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 4.87% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 22.61% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.84% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.17% |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | -150.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -150.77% |
| Dec 31, 2025 | -181.85% |
| Sep 30, 2025 | -79.61% |
| Jun 30, 2025 | -131.23% |
| Mar 31, 2025 | -128.12% |
| Dec 31, 2024 | -76.45% |
| Sep 30, 2024 | -67.77% |
| Jun 30, 2024 | -47.61% |
| Mar 31, 2024 | -110.06% |
| Dec 31, 2023 | -131.13% |
| Sep 30, 2023 | -63.41% |
| Jun 30, 2023 | -162.83% |
| Mar 31, 2023 | -44.15% |
| Dec 31, 2022 | 452.05% |
| Sep 30, 2022 | -127.98% |
| Jun 30, 2022 | -167.11% |
| Mar 31, 2022 | -146.30% |
| Dec 31, 2021 | 293.90% |
| Sep 30, 2021 | -119.95% |
| Jun 30, 2021 | -89.90% |
| Mar 31, 2021 | -98.58% |
| Dec 31, 2020 | -189.46% |
| Sep 30, 2020 | -55.72% |
| Jun 30, 2020 | -43.88% |
| Mar 31, 2020 | -81.38% |